304 related articles for article (PubMed ID: 12168829)
21. Relative efficacy of the opioid antagonist, naltrexone, on the initiation and promotion phases of rat mammary carcinogenesis.
Koo KL; Tejwani GA; Abou-Issa H
Anticancer Res; 1996; 16(4A):1893-8. PubMed ID: 8712718
[TBL] [Abstract][Full Text] [Related]
22. Feeding thiol-containing compounds, derived from vegetables, fails to inhibit N-methylnitrosourea-induced mammary tumorigenesis.
Cohen LA; Zhao Z; Pittman B; Aliaga C; Lubet R
Cancer Detect Prev; 2001; 25(3):254-61. PubMed ID: 11425267
[TBL] [Abstract][Full Text] [Related]
23. Effects of dietary folate on the development and progression of mammary tumors in rats.
Kotsopoulos J; Medline A; Renlund R; Sohn KJ; Martin R; Hwang SW; Lu S; Archer MC; Kim YI
Carcinogenesis; 2005 Sep; 26(9):1603-12. PubMed ID: 15888495
[TBL] [Abstract][Full Text] [Related]
24. Dietary effects of conjugated docosahexaenoic acid on N-methyl-N-nitrosourea-induced mammary carcinogenesis in female Sprague-Dawley rats.
Danbara N; Uehara N; Shikata N; Takada H; Hada T; Tsubura A
Oncol Rep; 2004 Nov; 12(5):1079-85. PubMed ID: 15492796
[TBL] [Abstract][Full Text] [Related]
25. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
26. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
O'Connor OA; Heaney ML; Schwartz L; Richardson S; Willim R; MacGregor-Cortelli B; Curly T; Moskowitz C; Portlock C; Horwitz S; Zelenetz AD; Frankel S; Richon V; Marks P; Kelly WK
J Clin Oncol; 2006 Jan; 24(1):166-73. PubMed ID: 16330674
[TBL] [Abstract][Full Text] [Related]
27. Interactions between 4-HPR and diet in NMU-induced mammary tumorigenesis.
Cohen LA; Epstein M; Saa-Pabon V; Meschter C; Zang E
Nutr Cancer; 1994; 21(3):271-83. PubMed ID: 8072880
[TBL] [Abstract][Full Text] [Related]
28. Effect of prolonged psychoemotional stress and melatonin on experimental mammary carcinogenesis in female rats.
Kassayová M; Friedmanová L; Orendás P; Kubatka P; Bojková B; Bobrov N; Ahlersová E; Ahlers I
Neoplasma; 2007; 54(3):251-5. PubMed ID: 17447859
[TBL] [Abstract][Full Text] [Related]
29. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.
Bischoff ED; Gottardis MM; Moon TE; Heyman RA; Lamph WW
Cancer Res; 1998 Feb; 58(3):479-84. PubMed ID: 9458093
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
31. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects.
Xu WS; Perez G; Ngo L; Gui CY; Marks PA
Cancer Res; 2005 Sep; 65(17):7832-9. PubMed ID: 16140952
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
Richon VM; Zhou X; Rifkind RA; Marks PA
Blood Cells Mol Dis; 2001; 27(1):260-4. PubMed ID: 11358386
[No Abstract] [Full Text] [Related]
33. Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents.
Dong G; Wang L; Wang CY; Yang T; Kumar MV; Dong Z
J Pharmacol Exp Ther; 2008 Jun; 325(3):978-84. PubMed ID: 18310471
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
Cooper AL; Greenberg VL; Lancaster PS; van Nagell JR; Zimmer SG; Modesitt SC
Gynecol Oncol; 2007 Mar; 104(3):596-601. PubMed ID: 17049973
[TBL] [Abstract][Full Text] [Related]
35. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.
Xu Y; Voelter-Mahlknecht S; Mahlknecht U
Int J Mol Med; 2005 Jan; 15(1):169-72. PubMed ID: 15583844
[TBL] [Abstract][Full Text] [Related]
36. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
Hsi LC; Xi X; Lotan R; Shureiqi I; Lippman SM
Cancer Res; 2004 Dec; 64(23):8778-81. PubMed ID: 15574791
[TBL] [Abstract][Full Text] [Related]
37. Dietary butyrate inhibits NMU-induced mammary cancer in rats.
Belobrajdic DP; McIntosh GH
Nutr Cancer; 2000; 36(2):217-23. PubMed ID: 10890033
[TBL] [Abstract][Full Text] [Related]
38. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
[TBL] [Abstract][Full Text] [Related]
39. Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
Ogawa T; Hayashi T; Tokunou M; Nakachi K; Trosko JE; Chang CC; Yorioka N
Cancer Res; 2005 Nov; 65(21):9771-8. PubMed ID: 16266998
[TBL] [Abstract][Full Text] [Related]
40. Estradiol and progesterone can prevent rat mammary cancer when administered concomitantly with carcinogen but do not modify surviving tumor histology, estrogen receptor alpha status or Ha-ras mutation frequency.
Swanson SM; Christov K
Anticancer Res; 2003; 23(4):3207-13. PubMed ID: 12931682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
